✦ LIBER ✦

P300 Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease

✍ Scribed by B. Feagan; C. Gasink; L.-L. Gao; M. Blank; J. Johanns; C. Guzzo; C.-F. Chiou; W. Sandborn; S.B. Hanauer; S. Targan; P. Rutgeerts; S. Ghosh; W. De Villiers; R. Panaccione; G. Greenberg; S. Schreiber; S. Lichtiger; B. Sands

Book ID: 119636791
Publisher: Oxford University Press
Year: 2012
Tongue: English
Weight: 67 KB
Volume: 6
Category: Article
ISSN: 1873-9946
DOI: 10.1016/s1873-9946(12)60320-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Multicenter, Randomized, Double-Blind,

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial

✍ William J. Sandborn; Christopher Gasink; Long-Long Gao; Marion Blank; Jewel Joha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Impact of ustekinumab on health-related

Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial

✍ Hidemi NAKAGAWA; Brad SCHENKEL; Mai KATO; Takeshi KATO; Atsuyuki IGARASHI; The J 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 French ⚖ 317 KB